Clorox Company (CLX) Form 4 Filings

Clorox (CLX) VP - CAO & Corp Controller Laurene E. Peck acquired 1,172 common shares on October 5, 2026, in settlement of a 2023 Performance Unit Grant that vested that day; she elected to defer the settlement under the 2005 Stock Incentive Plan. Clorox withheld 30 shares for tax obligations related to vesting performance stock units and 339 shares for tax obligations related to vesting restricted stock. Peck also held 100 shares indirectly through Trust of Parent.

Clorox Co. (CLX) EVP - Chief Admin Officer Kirsten Marriner acquired 6,637 common shares in settlement of a 2023 Performance Unit Grant that vested October 5, 2026. The company withheld 1,951 shares for taxes relating to vesting performance stock units and 2,142 shares for taxes relating to vesting restricted stock. A note tied to the restricted-stock entry says the resulting amount includes 721 shares acquired through a dividend reinvestment feature of the Company's Stock Incentive Plan. Each transaction entry lists $80.41 per share.

Clorox COO Chris T. Hyder reported acquiring 4,191 common shares through settlement of a 2023 Performance Unit Grant that vested October 5, 2026. Hyder elected to defer the settlement pursuant to the 2005 Stock Incentive Plan. The report also lists 100 shares withheld for tax obligations related to performance-stock-unit vesting and 1,532 shares withheld for tax obligations related to restricted-stock vesting, each at $80.41 per share.

Clorox Co. (CLX) EVP - Chief Legal Officer Angela C. Hilt reported acquiring 6,637 common shares on October 5, 2026, through settlement of a 2023 Performance Unit Grant that vested that day. The company withheld 2,296 shares for taxes on vested performance stock units and 2,351 shares for taxes on vesting restricted stock. A related footnote identifies 647 shares acquired through the company's Stock Incentive Plan dividend-reinvestment feature. A separate holding entry lists 669 shares indirectly held through a 401(k).

Clorox (CLX) EVP - Chief Financial Officer Luc Bellet reported the acquisition of 1,677 common shares upon settlement of a 2023 Performance Unit Grant that vested October 5, 2026. On that date, the company withheld 580 shares for taxes related to vesting performance stock units and 1,031 shares for taxes related to vesting restricted stock.

Clorox (CLX) officer Nina Barton, listed with the title “EVP-Chief Growth & Strategy Of,” had 1,106 common shares withheld by the company on October 5, 2026, to satisfy tax obligations relating to vesting of restricted stock. The reported price was $80.41 per share. Her directly held common-stock position afterward was 36,179 shares, including 121 shares acquired through the company’s Stock Incentive Plan dividend reinvestment feature.

Clorox (CLX) director Christopher J. Williams acquired 339.4642 deferred stock units on September 30, 2026, in lieu of quarterly director's fees, and 276.2573 units on August 28, 2026, through dividend reinvestment under the Independent Directors' Deferred Compensation Plan. His reported direct common-stock holding was 849 shares as of September 30, 2026. The deferred units will be settled 100% in Clorox stock in connection with his retirement or other termination of service as a director.

Clorox director Russell J. Weiner acquired 417 deferred stock units on September 30, 2026, in lieu of quarterly director’s fees, and 227 deferred stock units on August 28, 2026, through dividend reinvestment under the Independent Directors’ Deferred Compensation Plan. The units will be settled 100% in Clorox stock in connection with his retirement or other termination of service as a director.

Clorox director Matthew J. Shattock acquired 648.0681 Deferred Stock Units on September 30, 2026, in lieu of quarterly director's fees, and 255.3782 units on August 28, 2026, through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan.

Clorox director Stephanie Plaines acquired 339.4642 Deferred Stock Units on September 30, 2026, in lieu of quarterly director's fees. On August 28, 2026, she acquired 98.9603 Deferred Stock Units through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan. The units will be settled 100% in Clorox stock in connection with her retirement or other termination of service as a director.

Clorox director Pierre R. Breber acquired 416.6152 deferred stock units on September 30, 2026, in lieu of quarterly director’s fees, and 42.6144 units on August 28, 2026, through dividend reinvestment during the fiscal year under the Independent Directors’ Deferred Compensation Plan. The units will be settled 100% in Clorox stock upon Breber’s retirement or other termination of service as a director. Breber also reported 18,000 common shares held indirectly through a family trust as of September 30, 2026.

CLOROX CO (symbol: CLX) is the issuer of record for a Form 4 filing submitted to the SEC. Peck Laurene E reported acquisition or exercise transactions in this Form 4 filing.

CLOROX CO (CLX) reports that Laurene E. Peck, VP - CAO & Corp Controller, received an award of 2,192 restricted stock units on September 23, 2026. The reported per-share price was $83.9400. The units vest in 4 equal installments on October 5, 2027, October 5, 2028, October 5, 2029, and October 5, 2030.

After the award, Peck held 9,160 shares of common stock directly. The report also lists 100 shares held indirectly through the Trust of Parent.

Clorox (CLX) EVP - Chief Admin Officer Marriner Kirsten acquired an award of 12,389 restricted stock units on September 23, 2026. The transaction price was reported as $83.94 per share. The units vest in four equal installments, one-quarter on October 5, 2027, October 5, 2028, October 5, 2029, and October 5, 2030. Kirsten's reported direct holdings after the award were 76,683 shares. No Rule 10b5-1 plan is reported.

CLOROX CO (symbol: CLX) is the issuer of record for a Form 4 filing submitted to the SEC. Hyder Chris T reported acquisition or exercise transactions in this Form 4 filing.

Clorox EVP-Chief Operating Officer Chris T. Hyder was granted 13,342 shares of common stock on September 23, 2026; the transaction lists $83.94 per share. His direct holdings following the award were 90,202 shares. The related restricted stock units vest in four equal installments, one-quarter each on October 5, 2027, October 5, 2028, October 5, 2029, and October 5, 2030.

Clorox EVP and Chief Financial Officer Luc Bellet acquired 11,913 restricted stock units as an award on September 23, 2026; his reported directly held position after the transaction was 74,669 shares. The units vest in four equal installments, one-quarter each on October 5, 2027, 2028, 2029, and 2030. No Rule 10b5-1 plan is reported.

CLOROX CO (CLX) Chief Executive Officer Linda J. Rendle acquired 50,988 restricted stock units on September 23, 2026, in a grant/award transaction; the reported price per share was $83.94. Her directly held Common Stock position following the transaction was 252,149 shares. The units vest in four equal installments, one-quarter on each of October 5, 2027, 2028, 2029, and 2030. No Rule 10b5-1 plan is reported.

Clorox EVP Nina Barton acquired an award of 10,721 restricted stock units on September 23, 2026. Reported direct holdings following the transaction were 37,164 shares. The units vest in four equal installments on October 5, 2027, 2028, 2029, and 2030. No Rule 10b5-1 plan is reported.

CLOROX CO (symbol: CLX) is the issuer of record for a Form 4 filing submitted to the SEC. Hilt Angela C reported acquisition or exercise transactions in this Form 4 filing.

Clorox Co. EVP - Chief Legal Officer Angela C. Hilt received an award of 11,436 restricted stock units tied to common stock on September 23, 2026. The reported price was $83.9400 per share.

The units vest in four equal installments on October 5 of 2027, 2028, 2029 and 2030. After the award, Hilt reported 67,547 shares held directly; a separate holding lists 669 shares held indirectly through her 401(k).

Clorox executive Nina Barton reported a Form 4 reflecting a tax-withholding disposition, where the company withheld 1,681 shares of Common Stock at $95.69 per share to satisfy taxes on vesting of restricted stock. After this, she directly holds 26,443 shares, including 229 acquired via the Stock Incentive Plan’s dividend reinvestment feature. The transaction is not marked as pursuant to a Rule 10b5-1 plan.

Clorox executive Chris T. Hyder, EVP-Chief Operating Officer, reported a tax-related share withholding on 2026-07-15. The company withheld 277 shares of common stock at $94.75 per share to satisfy tax obligations tied to vesting restricted stock, leaving Hyder with 76,860 directly held shares, including 36 acquired through a dividend reinvestment feature.

Clorox director Christopher J. Williams reported two compensation-related awards of deferred stock units. On May 8, 2026, he received 297.0104 deferred stock units, and on June 30, 2026, he received 288.1391 deferred stock units.

The filing explains these units were acquired through dividend reinvestment during the fiscal year and by electing to receive quarterly director fees in deferred stock units under the Independent Directors' Deferred Compensation Plan. Each unit represents a 1-for-1 right to receive Clorox common stock, to be settled in shares after his retirement or other termination of board service. Following the latest award, Williams holds a total of 22,659.7313 deferred stock units directly.

Clorox director Russell J. Weiner reported two compensation-related grants of Deferred Stock Units, increasing his deferred equity-based holdings. He acquired 353.6253 Deferred Stock Units on June 30, 2026 and 242.2414 units on May 8, 2026, both recorded at a price of $0.0000 per unit as non-cash awards.

These units correspond 1-for-1 to shares of Clorox common stock and are linked to the company’s Independent Directors' Deferred Compensation Plan through dividend reinvestment and the election to receive quarterly director fees in Deferred Stock Units. After the June award, Weiner directly holds 18,599.8701 Deferred Stock Units, which will be settled entirely in Clorox stock upon his retirement or other termination of service as a director.

Clorox director Stephanie Plaines reported routine compensation-related awards of deferred stock units, not open-market trades. She acquired 288.1391 deferred stock units on June 30, 2026 and 103.9395 units on May 8, 2026, both at a stated price of $0.

The units were granted under the Independent Directors' Deferred Compensation Plan, including amounts acquired through dividend reinvestment and in lieu of quarterly director fees. After these awards, she held a total of 8,117.1272 deferred stock units, which will be settled entirely in Clorox common stock when she retires from, or otherwise leaves, the board.

Clorox director Pierre R. Breber reported changes in his equity-based compensation and holdings. He indirectly holds 18,000 shares of Clorox common stock through a trust. Separately, he acquired Deferred Stock Units in two transactions: 353.6253 units and 41.7110 units, each representing a right to receive one share of common stock.

The filing notes that these Deferred Stock Units were acquired through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director, and he now holds 3,495.4037 Deferred Stock Units directly.

Clorox director Matthew J. Shattock reported two non-cash awards of Deferred Stock Units. He acquired 550.0838 units on June 30, 2026 and 270.7961 units on May 8, 2026, tied to dividend reinvestment and electing fees in stock under the Independent Directors' Deferred Compensation Plan. These units, which track Clorox common stock 1-for-1, will be settled in Clorox shares when he retires or otherwise leaves the board. Following the most recent award, he directly holds 20,947.1472 Deferred Stock Units.

Bellet Luc reported acquisition or exercise transactions in this Form 4 filing.

Clorox Executive Vice President and Chief Financial Officer Luc Bellet received a grant of 42,118 shares in the form of restricted stock units at a reference price of $94.97 per share. These units will vest in full on June 17, 2029, increasing his direct holdings to 62,756 shares.

Hilt Angela C reported acquisition or exercise transactions in this Form 4 filing.

CLOROX CO executive Angela C. Hilt, EVP and Chief Legal Officer, received a grant of 26,324 shares of common stock on June 17, 2026, reported at $94.97 per share as a compensation award. These are in the form of Restricted Stock Units that will vest in full on June 17, 2029.

Following the award, she holds 56,111 common shares directly and 657.357 shares indirectly through a 401(k) plan. This filing reflects an equity compensation grant rather than an open‑market purchase or sale.

Marriner Kirsten reported acquisition or exercise transactions in this Form 4 filing.

Clorox executive Kirsten Marriner received a compensation-related stock grant. On June 17, 2026, the EVP – Chief Admin Officer was awarded 26,324 shares of Clorox common stock at a reference price of $94.97 per share. Following this award, her direct holdings increased to 64,294 shares.

The award is structured as Restricted Stock Units that will vest in three equal installments, with one-third scheduled to vest on each of June 17, 2027, June 17, 2028 and June 17, 2029, aligning incentives over multiple years.

Hyder Chris T reported acquisition or exercise transactions in this Form 4 filing.

Clorox executive Chris T. Hyder received a stock grant that increases his direct holdings. He was awarded 42,118 shares of Clorox common stock on June 17, 2026, as a grant or award valued at $94.97 per share. After this grant, he directly holds 77,087 shares. A related footnote states that these Restricted Stock Units will vest in full on June 17, 2029, three years after the grant date.

Clorox director Pierre R. Breber, through a trust, made an open-market purchase of 5,000 shares of Common Stock at a weighted average price of about $85.82 per share. Following this transaction, the trust’s indirect holdings increased to 18,000 Clorox shares.

The shares were bought in multiple trades within a price range from $85.19 to $86.01, according to the filing footnote.

Clorox Co (CLX) EVP and CFO Luc Bellet reported a routine tax-related share disposition. On vesting of restricted stock, the company withheld 244 shares of common stock at $103.63 per share to cover tax obligations, rather than selling shares in the open market.

After this withholding, Bellet directly holds 20,638 shares of Clorox common stock. Footnotes also note that this total includes 18 shares acquired through a dividend reinvestment feature under the company’s Stock Incentive Plan.

Clorox director Christopher J. Williams reported routine compensation-related awards of Deferred Stock Units. He acquired 265.3672 units on March 31, 2026 and 212.6390 units on February 13, 2026, with each unit representing one share of Clorox common stock.

Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and some in lieu of quarterly director fees. These Deferred Stock Units will be settled entirely in Clorox stock when Williams retires or otherwise leaves the board, bringing his reported Deferred Stock Unit balance to 22,074.5818 units held directly.

Clorox (CLX) director Russell J. Weiner reported routine compensation-related acquisitions of Deferred Stock Units. On February 13, 2026, he received 172.3630 Deferred Stock Units, and on March 31, 2026, he received 325.6779 Deferred Stock Units, each on a 1-for-1 basis linked to Clorox common stock.

According to the footnotes, some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and others in lieu of quarterly director fees. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director. Following these awards, his reported balance is 18,004.0034 Deferred Stock Units held directly.

Clorox director Pierre R. Breber reported routine compensation-related awards of Deferred Stock Units tied 1-for-1 to Clorox common stock. On March 31, 2026, he acquired 325.6779 Deferred Stock Units, bringing his holdings to 3100.0674 units. On February 13, 2026, he had received an additional 27.0502 units.

According to the disclosures, some Deferred Stock Units were acquired through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan and some were received in lieu of quarterly director fees. These units will be settled entirely in Clorox stock when Breber retires or otherwise leaves the board, and do not reflect open-market buying or selling.

Clorox director Matthew J. Shattock reported routine equity-based compensation in the form of deferred stock units. He acquired 506.6101 deferred stock units on March 31, 2026 and 191.2909 units on February 13, 2026, each on a 1-for-1 basis with Clorox common stock.

The units were received through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan and will be settled in Clorox stock after his retirement or other termination of board service. Following these awards, he directly holds 20,126.2673 deferred stock units.

Clorox director Stephanie Plaines reported awards of deferred stock units that increase her equity-based compensation stake. She acquired 265.3672 deferred stock units on March 31, 2026 and 72.7316 units on February 13, 2026, both at a stated price of $0.00 per unit as non-cash awards.

The units are credited 1-for-1 in relation to Clorox common stock and arise from dividend reinvestment during the fiscal year and receipt of deferred units instead of quarterly director fees under the Independent Directors' Deferred Compensation Plan. Following the latest award, she holds a total of 7,725.0486 deferred stock units, which will be settled entirely in Clorox stock upon her retirement or other termination of board service.

Clorox executive Chris T. Hyder reported a small tax-related share disposition. On the vesting of restricted stock, 41 shares of Clorox common stock were withheld by the company at $108.73 per share to satisfy tax obligations, a routine non-market transaction.

After this withholding, Hyder directly holds 34,969 shares of Clorox common stock, which the disclosure notes includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan.

Clorox executive Stacey Grier reported a small, routine share disposition tied to taxes rather than a market trade. On vesting of restricted stock, the company withheld 32 shares of common stock at a value of $108.73 per share to cover tax obligations.

After this tax-withholding disposition, Grier directly holds 32,116 Clorox shares. This total includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan, indicating the filing reflects compensation and administrative activity rather than an open-market sale.

The Clorox Company director reports new deferred stock units tied to CLX common stock. A Form 4 filing shows acquisitions of derivative securities classified as deferred stock units on several 2025 dates. These units convert into Clorox common stock on a 1-for-1 basis.

The director acquired 227.0333 deferred stock units on 11/06/2025 and additional amounts of 1,637.8577 and 272.7363 deferred stock units on 12/31/2025, all at a price of $0.0000 per unit. Following these transactions, the director directly beneficially owns 21,596.5756 deferred stock units.

The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent an annual award under the 2005 Stock Incentive Plan, and others reflect electing to receive quarterly director fees in deferred stock units. These units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.

Clorox Company director equity compensation and fee deferral is reported in this insider trading disclosure. The filing shows several awards of deferred stock units, each representing the right to receive an equal number of Clorox common shares.

On 11/06/2025, the director acquired 179.1424 deferred stock units at an exercise price of $0.0000, bringing the balance to 15,533.383 units held directly. On 12/31/2025, the director acquired an additional 1,637.8577 deferred stock units and a further 334.7218 units, increasing direct holdings to about 17,505.9625 deferred stock units.

The disclosure notes that some units were obtained through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, others as the annual deferred stock unit award under the 2005 Stock Incentive Plan, and others received instead of quarterly director cash fees. The units will be settled 100% in Clorox stock upon the director’s retirement or other termination of board service.

The Clorox Company director reports additional deferred stock units related to board compensation and dividend reinvestment. On November 6, 2025, the director acquired 199.1684 deferred stock units, each convertible into one share of Clorox common stock, at a price of $0.0000 per unit, bringing the total beneficially owned to 17,269.8302 units.

On December 31, 2025, the director received an additional 1,637.8577 deferred stock units as an annual award and 520.6784 deferred stock units in lieu of quarterly director fees, increasing total holdings to 19,428.3663 deferred stock units. These units are credited under Clorox’s independent director compensation plans and will be settled in Clorox stock when the director retires or otherwise leaves the board.

The Clorox Company director reported several deferred stock unit transactions. On 11/06/2025, the director acquired 63.1574 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan on a 1-for-1 basis with Clorox common stock. On 12/31/2025, the director received 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, and 272.7363 deferred stock units in lieu of quarterly director fees. All units have an exercise price of $0.0000 and each unit represents one share of Clorox common stock. Following these transactions, the director beneficially owns 7,386.9498 deferred stock units, which will be settled in Clorox stock upon retirement or other termination of service as a director.

Clorox Co. (CLX) disclosed a Form 4 for a director reporting routine deferred stock unit activity during 2025. The filing shows multiple acquisitions of deferred stock units tied to Clorox common stock, including 74.9914 units on 02/14/2025, 82.9936 on 05/09/2025, 97.043 on 08/29/2025, 109.0592 on 11/06/2025, and an annual award of 1,637.8577 units on 12/31/2025, all at a price of $0.0000.

After these transactions, the director beneficially owns 11,094.3468 deferred stock units directly. The units are credited on a 1-for-1 basis and will be settled 100% in Clorox stock in connection with the director’s retirement or other termination of service. Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and the year-end grant was made under the 2005 Stock Incentive Plan.

The Clorox Company director reported routine equity compensation activity in the form of deferred stock units. The filing shows several acquisitions of deferred stock units tied to Clorox common stock during 2025, including transactions dated 02/14/2025, 05/09/2025, 08/29/2025, 11/06/2025, and 12/31/2025. These awards were recorded at an exercise price of $0.0000 per unit.

The director’s beneficial holdings in these derivative securities increased to 15,677.4328 deferred stock units held directly. The explanation notes that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, while an additional annual award was granted under the 2005 Stock Incentive Plan. Each deferred stock unit represents a 1-for-1 right to receive Clorox stock, to be settled in shares upon the director’s retirement or other termination of service from the board.

The Clorox Company director reports routine deferred stock awards. A board member of Clorox (ticker CLX) reported several grants of deferred stock units that each convert 1-for-1 into Clorox common stock. On 11/06/2025, the director acquired 219.3396 deferred stock units, bringing the beneficial holding to 19,018.8638 units. On 12/31/2025, additional awards of 1,219.1572 and 145.2617 deferred stock units increased the total to 20,383.2827 units held directly.

The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent the annual deferred stock unit award under the 2005 Stock Incentive Plan, and some reflect stock units received instead of a portion of quarterly director fees. All deferred stock units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.

Clorox Co. director deferred stock unit grants and reinvestments

A director of Clorox Co. reported multiple acquisitions of deferred stock units tied to Clorox common stock during 2025. On several dates, including 02/14/2025, 05/09/2025, 08/29/2025, and 11/06/2025, small fractional amounts of deferred stock units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, each at an exercise price of $0.0000 and on a 1-for-1 basis into Clorox stock.

On 12/31/2025, the director received an additional 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, also with a conversion price of $0.0000. Following these transactions, the director beneficially owned a total of 4,471.9997 deferred stock units, which will be settled 100% in Clorox stock upon retirement or other termination of service as a director.

Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.

On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.

The Clorox Company reported a routine equity grant to a director. On 12/31/2025, the director received an annual award of 1-for-1 Deferred Stock Units under the company’s 2005 Stock Incentive Plan. The transaction, reported on a Form 4 for one reporting person, shows 1,637.8577 Deferred Stock Units credited at a price of $0.0000 per unit.

The Deferred Stock Units are tied to Clorox common stock and will be settled 100% in Clorox shares in connection with the director’s retirement or other termination of board service. The filing characterizes this as an annual award, reflecting ongoing non-cash compensation for board service rather than an open-market purchase or sale.

The Clorox Company director reports a routine stock-based compensation grant. A board member received an annual award of 825.0862 Deferred Stock Units on 12/31/2025 under the company’s 2005 Stock Incentive Plan. Each unit is described as a 1-for-1 right tied to a share of Clorox common stock, with a stated price of $0.0000 per unit, indicating this is a compensation award rather than an open‑market purchase. The filing states these Deferred Stock Units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board, so the director’s economic interest in the company increases but actual shares will be issued in the future.